Small Molecules

03 Feb 2020 Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
03 Feb 2020 Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
03 Feb 2020 Mesoblast submits completed biologics license application for Ryoncil to US FDA
02 Feb 2020 Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
02 Feb 2020 Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
02 Feb 2020 Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
02 Feb 2020 Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
02 Feb 2020 AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
02 Feb 2020 AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
02 Feb 2020 CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia
02 Feb 2020 EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
31 Jan 2020 Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial
31 Jan 2020 Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)
30 Jan 2020 Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
30 Jan 2020 Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder
30 Jan 2020 FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb
30 Jan 2020 Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
30 Jan 2020 Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
30 Jan 2020 Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
30 Jan 2020 vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
30 Jan 2020 Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
30 Jan 2020 Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
30 Jan 2020 Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
28 Jan 2020 Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
28 Jan 2020 Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up